Cresset Asset Management’s Biogen BIIB Stock Holding History

Cresset Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-76,400	Closed	-$13.4M	–	1665
2025 Q4	$13.4M	Buy	+76,400	New	+$12.5M	0.06%	204
2025 Q2	–	Sell	-39,700	Closed	-$5.43M	–	1473
2025 Q1	$5.43M	Buy	+39,700	New	+$5.68M	0.03%	337

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cresset Asset Management's BIIB Position: Q1 2026 in Review

Cresset Asset Management reduced its Biogen (BIIB) stake by 12% in Q1 2026, selling an estimated $1.64M and leaving 67,503 shares worth $12.4M. The position accounts for 0.05% of the portfolio, ranked #215.

Cresset Asset Management first reported a position in BIIB in Q4 2018 and has held it in 29 quarters since. The position peaked at $13.4M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Cresset Asset Management held 67,503 shares of Biogen worth $12.4M as of Q1 2026.
Cresset Asset Management sold 8,876 Biogen shares in Q1 2026, an estimated $1.64M.
Biogen made up 0.05% of Cresset Asset Management's portfolio in Q1 2026, its #215 holding.
Cresset Asset Management first reported a position in Biogen in Q4 2018 and has held it in 29 quarters since.
Cresset Asset Management's Biogen position peaked at $13.4M in Q4 2025.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.